Figure 7.
Neither docetaxel nor vincristine triggers activation of the UPR in melanoma cells. (A) Mel-RM and MM200 cells with or without treatment with TM (3 µM), docetaxel (20 nM), or vincristine (50 ng/ml) for indicated periods were subjected to Western blot analysis. (B) Mel-RM and MM200 cells with or without treatment with TM (3 µM), docetaxel (20 nM), or vincristine (50 ng/ml) for 16 hours. Reverse transcription-polymerase chain reaction products of XBP1 mRNA were digested with Apa-LI for 90 minutes followed by electrophoresis. (C) Melanoma cells were treated with TM (3 µM), docetaxel (20 nM), or vincristine (50 ng/ml) for 16 hours. Whole cell lysates were subjected to Western blot analysis. The data shown are representative of three individual experiments.